Lung Cancer Research Foundation Welcomes New Members of Board of Directors

NEW YORK, June 2, 2021 /PRNewswire/ — The Lung Cancer Research Foundation (LCRF) is pleased to welcome two new members of its board of directors, Colleen Conner Ziegler and Bruce Dunbar.

Colleen Conner Ziegler recently joined LCRF’s board of directors. She is a lung cancer survivor and active patient advocate, who was diagnosed with stage IV ALK-positive non-small cell lung cancer at age 58 in May 2015. She started, and is currently receiving, Alectinib as her first line of treatment, acknowledging that research has made her treatment possible.

After a career spanning twenty-two years in the pharmaceutical industry, Ms. Conner Ziegler has served in a variety of community-oriented activities, including serving on various boards of directors and advisory boards. Her primary focus prior to her diagnosis was on child rearing and women’s health issues.

After her lung cancer diagnosis, she turned her attention to lung cancer advocacy. Her advocacy includes:

Founding member of Life and Breath (LAB), a grass-root lung cancer organization, aiming to raise lung cancer awareness and funding for research Founding member of ALKFusion, a patient-driven organization whose vision is to initiate and support patients’ central research Currently active ALKFusion representative, member of the Lung Cancer Action Network, member of the LCRF Strategic Plan Taskforce Participated in the Department of Defense Lung Cancer Research Program Volunteer of the Lungevity Peer-to-Peer mentoring program that connects newly diagnosed patients with a mentor to guide them through their diagnosis and treatment Participated in patient-centered videos and printed materials on lung cancer diagnosis, advocacy and living with lung cancer and Genentech’s ALK Positivity Project Volunteering at GO2’s Annual Voices Summit Co-authored and presented patient advocacy poster on the 2019 World Conference on Lung Cancer, Barcelona, ​​Spain

Ms. Conner Ziegler lives in Rochester, New York with her husband, Tom, and their daughter Taya.

Bruce Dunbar has joined the board of the LCRF after being involved with the organization since his diagnosis of stage IV non-small cell lung cancer in 2017. As a direct beneficiary of lung cancer research, Mr. Dunbar is an active advocate for further efforts to improve screening. to improve , detection and treatment. In addition to his involvement with LCRF, he serves as a consumer reviewer for the Congressionally Directed Medical Research Program’s Lung Cancer Program and advocates for federal funding for lung cancer research through the GO2 Foundation’s annual Voices Summit.

Mr. Dunbar’s career spans more than 30 years in various corporate communications, marketing and advertising roles, including Senior Vice President and Director of Corporate Communications for OppenheimerFunds, Inc. and Managing Director, Head of Wealth Management Communications, for Morgan Stanley. He has also held senior client advisory roles at Teneo and Finsbury, Glover, Herrington and is currently a partner in communications advisor Coppertop Media.

mr. Dunbar holds an AB in History from Princeton University and an MBA from Columbia University’s Graduate School of Business.

“We are delighted to welcome both Ms. Conner Ziegler and Mr. Dunbar to the LCRF Board of Directors,” said Dennis Chillemi, Executive Director. “Their patient experience, passion for research, personal philanthropy and many connections within the lung cancer community will provide LCRF with a more diverse perspective as we continue to bring hope to the lung cancer community through research.”

For more information about LCRF and the Board of Directors, visit

About the Lung Cancer Research Foundation (LCRF)

The Lung Cancer Research Foundation® (LCRF) is the leading non-profit organization focused on funding innovative, high-paying research with the potential to extend survival and improve the quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer. To date, LCRF has funded 383 research grants, totaling nearly $36 million, the highest amount provided by a nonprofit dedicated to funding lung cancer research. For more information, visit

Sheila Sullivan
sr. Director, Marketing & Communication, LCRF
[email protected]

SOURCE Lung Cancer Research Foundation

Related Links

Comments are closed.